- Posted by atatarko
- 0 Comments
Edition JNCCN has published first documentary case of KIT mutation activation in the neuroendocrine tumor treatment (NET), and the successful treatment with kinesin inhibitor 11 (KIF11) and imatinib. 48-year-old patient with intractable metastatic NET, not responding to the use of traditional chemotherapy was treated using kinesin inhibitor 11 (KIF11) in the first phase of the clinical trial, which gave an opportunity to see a considerable effect. After two weeks of treatment with imatinib the patient’s pain was reduced and the presence of the disease was much less noticeable.
To view the full text of the article click here